Respirerx Pharmaceuticals Inc Share Price Other OTC
Equities
US2205243007
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Sales 2021 | - | Sales 2022 | - | Capitalization | 289K 24.04M |
---|---|---|---|---|---|
Net income 2021 | -3M -250M | Net income 2022 | -2M -167M | EV / Sales 2021 | - |
Net Debt 2021 | 2.08M 173M | Net Debt 2022 | 2.71M 226M | EV / Sales 2022 | - |
P/E ratio 2021 |
-0.29
x | P/E ratio 2022 |
-0.06
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 93.37% |
Managers | Title | Age | Since |
---|---|---|---|
Arnold Lippa
CEO | Chief Executive Officer | 77 | 22/13/22 |
Jeff Margolis
DFI | Director of Finance/CFO | 68 | 22/13/22 |
Richard Purcell
CTO | Chief Tech/Sci/R&D Officer | 63 | 15/14/15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Arnold Lippa
CEO | Chief Executive Officer | 77 | 22/13/22 |
Director/Board Member | - | 22/23/22 | |
Jeff Margolis
DFI | Director of Finance/CFO | 68 | 22/13/22 |
1st Jan change | Capi. | |
---|---|---|
+8.63% | 115B | |
+13.17% | 107B | |
-12.76% | 22.31B | |
-3.99% | 21.6B | |
-7.19% | 18.23B | |
-39.93% | 17.62B | |
+6.67% | 14.26B | |
+33.90% | 12.37B | |
-28.60% | 8.28B |